RYTM
Price
$103.48
Change
+$1.79 (+1.76%)
Updated
Sep 4, 02:36 PM (EDT)
Capitalization
6.76B
68 days until earnings call
VRNA
Price
$106.14
Change
-$0.03 (-0.03%)
Updated
Sep 4, 02:45 PM (EDT)
Capitalization
9.18B
68 days until earnings call
Interact to see
Advertisement

RYTM vs VRNA

Header iconRYTM vs VRNA Comparison
Open Charts RYTM vs VRNABanner chart's image
Rhythm Pharmaceuticals
Price$103.48
Change+$1.79 (+1.76%)
Volume$432
Capitalization6.76B
Verona Pharma
Price$106.14
Change-$0.03 (-0.03%)
Volume$200
Capitalization9.18B
RYTM vs VRNA Comparison Chart in %
Loading...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RYTM vs. VRNA commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RYTM is a Hold and VRNA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (RYTM: $101.69 vs. VRNA: $106.17)
Brand notoriety: RYTM and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RYTM: 82% vs. VRNA: 25%
Market capitalization -- RYTM: $6.76B vs. VRNA: $9.18B
RYTM [@Biotechnology] is valued at $6.76B. VRNA’s [@Biotechnology] market capitalization is $9.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RYTM’s FA Score shows that 1 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • RYTM’s FA Score: 1 green, 4 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both RYTM and VRNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RYTM’s TA Score shows that 3 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • RYTM’s TA Score: 3 bullish, 4 bearish.
  • VRNA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both RYTM and VRNA are a bad buy in the short-term.

Price Growth

RYTM (@Biotechnology) experienced а -0.60% price change this week, while VRNA (@Biotechnology) price change was +0.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.27%. For the same industry, the average monthly price growth was +7.08%, and the average quarterly price growth was +29.28%.

Reported Earning Dates

RYTM is expected to report earnings on Nov 11, 2025.

VRNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($9.18B) has a higher market cap than RYTM($6.76B). VRNA YTD gains are higher at: 128.618 vs. RYTM (81.654). VRNA has higher annual earnings (EBITDA): -34.62M vs. RYTM (-159.11M). VRNA has more cash in the bank: 438M vs. RYTM (291M). RYTM has less debt than VRNA: RYTM (4.19M) vs VRNA (244M). VRNA has higher revenues than RYTM: VRNA (222M) vs RYTM (156M).
RYTMVRNARYTM / VRNA
Capitalization6.76B9.18B74%
EBITDA-159.11M-34.62M460%
Gain YTD81.654128.61863%
P/E RatioN/AN/A-
Revenue156M222M70%
Total Cash291M438M66%
Total Debt4.19M244M2%
FUNDAMENTALS RATINGS
RYTM vs VRNA: Fundamental Ratings
RYTM
VRNA
OUTLOOK RATING
1..100
2221
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
172
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3636
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRNA's Valuation (82) in the Pharmaceuticals Other industry is in the same range as RYTM (98) in the Biotechnology industry. This means that VRNA’s stock grew similarly to RYTM’s over the last 12 months.

VRNA's Profit vs Risk Rating (2) in the Pharmaceuticals Other industry is in the same range as RYTM (17) in the Biotechnology industry. This means that VRNA’s stock grew similarly to RYTM’s over the last 12 months.

VRNA's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as RYTM (100) in the Biotechnology industry. This means that VRNA’s stock grew similarly to RYTM’s over the last 12 months.

VRNA's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as RYTM (36) in the Biotechnology industry. This means that VRNA’s stock grew similarly to RYTM’s over the last 12 months.

VRNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as RYTM (100) in the Biotechnology industry. This means that VRNA’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RYTMVRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 25 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VRTTX551.022.33
+0.42%
Vanguard Russell 3000 Index I
RGAFX85.220.33
+0.39%
American Funds Growth Fund of Amer R5
GISYX17.810.03
+0.17%
Grandeur Peak Intl Stalwarts Instl
MKSPX30.510.01
+0.03%
BlackRock Advantage SMID Cap K
FLEKX12.95-0.02
-0.15%
Victory Pioneer Equ Premium Income R6

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with VRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then VRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-2.42%
VRNA - RYTM
46%
Loosely correlated
+0.07%
CRNX - RYTM
44%
Loosely correlated
+4.05%
RVMD - RYTM
42%
Loosely correlated
+0.61%
OCUL - RYTM
41%
Loosely correlated
+1.89%
IDYA - RYTM
40%
Loosely correlated
+1.10%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with RYTM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
+0.07%
RYTM - VRNA
45%
Loosely correlated
-2.42%
ZYME - VRNA
42%
Loosely correlated
+0.93%
IRON - VRNA
42%
Loosely correlated
+0.31%
CRNX - VRNA
37%
Loosely correlated
+4.05%
OCUL - VRNA
37%
Loosely correlated
+1.89%
More